Cancel

Multiple Myeloma: Enhancing Treatment Tolerability, Adherence, and Patient-Centered Care

STATEMENT OF NEED Multiple myeloma (MM) is a B-cell neoplasm characterized by aberrant expansion of plasma cells within the bone marrow and extramedullary sites (eg, cortical bone). Approximately 32,270 new cases of MM are diagnosed in the United States annually and 12,830 people die of the disease. Although the tumor cells remain primarily within the bone marrow, they can cause a number of complications, including localized bone destruction, anemia, decreased immunity to infection, and kid...
i3 Health

Virtual Tumor Board: Diagnosis and Management of Myelodysplastic Syndromes

STATEMENT OF NEED Myelodysplastic syndromes (MDS) are a group of heterogeneous hematopoietic disorders derived from an abnormal multipotent progenitor cell, characterized by ineffective hematopoiesis, bone marrow failure, and peripheral blood cytopenias. Survival in MDS ranges from a median of 5.3 years in lower-risk patients to as little as 0.8 years in higher-risk patients. Mortality is usually a result of infection, hemorrhage, and/or iron overload secondary to red blood cell transfusion...
i3 Health

Shaping the Future of Myeloma Treatment

To help hematologist-oncologists keep pace with new advancements in multiple myeloma therapeutic regimens and management strategies, Shaping the Future of Myeloma Treatment features a roundtable discussion in which a panel of myeloma experts addresses a number of key clinical topics. Learners who participate in these activities will be expected to improve their ability to individualize treatment plans, based on genomics and risk stratification, to achieve durable remission while minimizing tox...
This CME-certified enduring activity is jointly provided by Penn State College of Medicine, RedMedEd, and the Multiple Myeloma Research Foundation.

Eradication of Minimal Residual Disease in Multiple Myeloma: The Role and Timing of ASCT

Advances in multiple myeloma (MM) management have equipped oncology health care providers with the tools and strategies for achieving treatment responses in up to 100% of patients, with as many as 80% reaching a complete response (CR). However, achieving a CR does not always predict long-term survival, and most patients ultimately relapse as a result of the persistence of minimal residual disease (MRD) after treatment. MRD cannot be detected with conventional, low-sensitivity evaluation method...
Albert Einstein College of Medicine

Current Obstacles in Myeloma Management: Debating the Evidence

ACTIVITY DESCRIPTION The clinical multiple myeloma arena has seen significant advances in treatment, diagnosis, imaging, disease monitoring, and supportive care. The approval of several new agents has led to expanded criteria for earlier-stage diagnosis in some higher-risk patients with smoldering multiple myeloma (SMM), though questions remain regarding optimal treatment of other SMM patients. Treatment advances have improved median survival; nevertheless, prognosis remains poor for some pat...
Multiple Myeloma Research Foundation, RedMedEd, and Penn State College of Medicine

Osler Radiation Oncology Online Review

The Osler Institute utilized state of the art equipment to record the comprehensive Radiation Oncology Review Course and bring it to you! These audio files are stored “in the cloud” so you can stream them anywhere, anytime, as long as you have an internet connection – your learning experience is almost like being at the live activity, but without travel costs and time away from your practice. The Osler Radiation Oncology Review also offers a variety of live Radiation Oncology board revie...
Osler Institute

Osler Surgery MOC Online Review

The Osler Institute utilized state of the art equipment to record the comprehensive Radiation Oncology Review Course and bring it to you! These audio files are stored “in the cloud” so you can stream them anywhere, anytime, as long as you have an internet connection – your learning experience is almost like being at the live activity, but without travel costs and time away from your practice. The Osler Radiation Oncology Review also offers a variety of live Radiation Oncology board revie...
Osler Institute

Nursing Management of Bone Health in Patients With Cancer

STATEMENT OF NEED Many tumors, such as prostate, breast, lung, and multiple myeloma, affect bone health. Once cancer spreads to the skeletal system, the risk for pain, fractures, hypercalcemia, and nerve compression increases considerably. Several studies have shown that the use of antiresorptive agents such as bisphosphonates and monoclonal antibodies can reduce the morbidity of skeletal complications in patients with cancer and significantly improve quality of life. Combined with preventi...
i3 Health

RXinsider, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps. RXinsider, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map.